The Changing Epidemiology and Antimicrobial Susceptibility of Staphylococcus aureus Isolated from Blood Cultures in a University Hospital from Argentina
Restricted accessResearch articleFirst published online March, 2024
The Changing Epidemiology and Antimicrobial Susceptibility of Staphylococcus aureus Isolated from Blood Cultures in a University Hospital from Argentina
Staphylococcus aureus bacteremia (SAB) is one of the most common serious bacterial infections worldwide. In this study, we demonstrated changes in SAB epidemiology in an Argentinean University Hospital during an 8-year period (2009–2016). A total of 326 S. aureus clinical isolates were recovered in three periods: P1: 2009–2010, P2: 2012–2014, and P3: 2015–2016. Among these, 127 were methicillin-resistant S. aureus (MRSA) and were characterized by phenotypic and molecular methods. We hereby report a significant decline in multiple drug resistance among MRSA isolates associated with an increase in SCCmec IV between the three periods. A diversity of MRSA-IV clones (mainly ST30-MRSA-IV, ST5-MRSA-IV, and ST8-MRSA-IV) replaced between 2009 and 2016 the previous prevalent MRSA clone causing bloodstream infections at this hospital (ST5-MRSA-I). MRSA population structure continued to diversify between P2 and P3. Notably, ST8-MRSA-IV-t008 related to USA300 was first detected during P2, and ST8-MRSA-IV together with ST30-MRSA-IV related to the Southwest Pacific clone were the more prevalent MRSA genotypes circulating during P3.
Get full access to this article
View all access options for this article.
References
1.
TongSYC, DavisJS, EichenbergerE, et al.Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev, 2015; 28(3):603–661; doi: 10.1128/CMR.00134-14
2.
van HalSJ, JensenSO, VaskaVL, et al.Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev, 2012; 25(2):362–386; doi: 10.1128/CMR.05022-11
3.
WhitbyM, McLawsML, BerryG. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: A meta-analysis. Med J Aust, 2001; 175(5):264–267; doi: 10.5694/j.1326-5377.2001.tb143562.x
4.
KourtisAP, HatfieldK, BaggsJ, et al.Vital signs: Epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections—United States. MMWR Morb Mortal Wkly Rep, 2019; 68(9):214–219; doi: 10.15585/mmwr.mm6809e1
5.
HassounA, LindenPK, FriedmanB. Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment. Crit Care Lond Engl, 2017; 21(1):211; doi: 10.1186/s13054-017-1801-3
6.
JooE-J, ParkDA, KangC-I, et al.Reevaluation of the impact of methicillin-resistance on outcomes in patients with Staphylococcus aureus bacteremia and endocarditis. Korean J Intern Med, 2019; 34(6):1347–1362; doi: 10.3904/kjim.2017.098
7.
JinY, ZhouW, ZhanQ, et al.Genomic epidemiology and characterization of methicillin-resistant Staphylococcus aureus from bloodstream infections in China. mSystems, 2021; 6(6):e0083721; doi: 10.1128/mSystems.00837-21
8.
MiuraY, YamaguchiT, NakamuraI, et al.Epidemiological trends observed from molecular characterization of methicillin-resistant Staphylococcus aureus isolates from blood cultures at a Japanese University Hospital, 2012–2015. Microb Drug Resist Larchmt N, 2018; 24(1):70–75; doi: 10.1089/mdr.2017.0008
9.
SeasC, GarciaC, SallesMJ, et al.Staphylococcus aureus bloodstream infections in Latin America: Results of a multinational prospective cohort study. J Antimicrob Chemother, 2018; 73(1):212–222; doi: 10.1093/jac/dkx350
10.
LoewenK, SchreiberY, KirlewM, et al.Community-associated methicillin-resistant Staphylococcus aureus infection. Can Fam Physician, 2017; 63(7):512–520.
11.
SkovRL, JensenKS. Community-associated meticillin-resistant Staphylococcus aureus as a cause of hospital-acquired infections. J Hosp Infect, 2009; 73(4):364–370; doi: 10.1016/j.jhin.2009.07.004
12.
AriasCA, ReyesJ, CarvajalLP, et al.A prospective cohort multicenter study of molecular epidemiology and phylogenomics of Staphylococcus aureus bacteremia in nine Latin American countries. Antimicrob Agents Chemother, 2017; 61(10):e00816–e00817; doi: 10.1128/AAC.00816-17
13.
MenocalA, LuceroC, GagettiP, et al.Staphylococcus aureus: Perfil de sensibilidad a los antimicrobianos 2010–2017. Programa Nacional de Vigilancia de la Resistencia a los Antimicrobianos, WHONET—Argentina. XV Congr Argent Microbiol CAM2019, 2019; 1.
14.
FernandezS, de VediaL, Lopez FurstMJ, et al.Methicillin-resistant Staphylococcus aureus ST30-SCCmec IVc clone as the major cause of community-acquired invasive infections in Argentina. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis, 2013; 14:401–405; doi: 10.1016/j.meegid.2012.12.018
15.
YehY-C, YehK-M, LinT-Y, et al.Impact of vancomycin MIC creep on patients with methicillin-resistant Staphylococcus aureus bacteremia. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi, 2012; 45(3):214–220; doi: 10.1016/j.jmii.2011.11.006
16.
LodiseTP, GravesJ, EvansA, et al.Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother, 2008; 52(9):3315–3320; doi: 10.1128/AAC.00113-08
17.
NivedithaN, SujathaS. Worrisome trends in rising minimum inhibitory concentration values of antibiotics against methicillin resistant Staphylococcus aureus—Insights from a tertiary care center, South India. Braz J Infect Dis Off Publ Braz Soc Infect Dis, 2015; 19(6):585–589; doi: 10.1016/j.bjid.2015.08.005
18.
RossatoAM, Primon-BarrosM, DiasCAG, et al.Vancomycin MIC and agr dysfunction in invasive MRSA infections in southern Brazil. Braz J Microbiol Publ Braz Soc Microbiol, 2020; 51(4):1819–1823; doi: 10.1007/s42770-020-00384-0
19.
CastroBE, BerrioM, VargasML, et al.Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America. J Antimicrob Chemother, 2020; 75(9):2424–2431; doi: 10.1093/jac/dkaa221
20.
Di GregorioS, PerazziB, OrdoñezAM, et al.Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital. Microb Drug Resist Larchmt N, 2015; 21(1):25–34; doi: 10.1089/mdr.2014.0190
21.
Performance Standards for Antimicrobial Susceptibility TestingCLSI. 26th Edition. 2016.
22.
MagiorakosA-P, SrinivasanA, CareyRB, et al.Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, 2012; 18(3):268–281; doi: 10.1111/j.1469-0691.2011.03570.x
23.
MurakamiK, MinamideW, WadaK, et al.Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction. J Clin Microbiol, 1991; 29(10):2240–2244; doi: 10.1128/jcm.29.10.2240-2244.1991
24.
LinaG, PiémontY, Godail-GamotF, et al.Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis, 1999; 29(5):1128–1132; doi: 10.1086/313461
25.
KondoY, ItoT, MaXX, et al.Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: Rapid identification system for mec, ccr, and major differences in junkyard regions. Antimicrob Agents Chemother, 2007; 51(1):264–274; doi: 10.1128/AAC.00165-06
26.
ChungM, de LencastreH, MatthewsP, et al.Molecular typing of methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis: Comparison of results obtained in a multilaboratory effort using identical protocols and MRSA strains. Microb Drug Resist Larchmt N, 2000; 6(3):189–198; doi: 10.1089/mdr.2000.6.189
27.
GardellaN, von SpechtM, CuiroloA, et al.Community-associated methicillin-resistant Staphylococcus aureus, eastern Argentina. Diagn Microbiol Infect Dis, 2008; 62(3):343–347; doi: 10.1016/j.diagmicrobio.2008.07.008
28.
SolaC, GribaudoG, VindelA, et al.Identification of a novel methicillin-resistant Staphylococcus aureus epidemic clone in Córdoba, Argentina, involved in nosocomial infections. J Clin Microbiol, 2002; 40(4):1427–1435; doi: 10.1128/JCM.40.4.1427-1435.2002
29.
EnrightMC, DayNP, DaviesCE, et al.Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol, 2000; 38(3):1008–1015; doi: 10.1128/JCM.38.3.1008-1015.2000
30.
HarmsenD, ClausH, WitteW, et al.Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol, 2003; 41(12):5442–5448; doi: 10.1128/JCM.41.12.5442-5448.2003
31.
KatzBD, LuperchioSA, ThorneGM. Detection of daptomycin-nonsusceptible strains using the Neo-Sensitab prediffusion method. Diagn Microbiol Infect Dis, 2008; 61(3):315–320; doi: 10.1016/j.diagmicrobio.2008.01.021
32.
van HalSJ, WehrhahnMC, BarbagiannakosT, et al.Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol, 2011; 49(4):1489–1494; doi: 10.1128/JCM.02302-10
33.
Core TeamR. R: A Language and Environment for Statistical Computing; 2022.
34.
EgeaAL, GagettiP, LamberghiniR, et al.New patterns of methicillin-resistant Staphylococcus aureus (MRSA) clones, community-associated MRSA genotypes behave like healthcare-associated MRSA genotypes within hospitals, Argentina. Int J Med Microbiol, 2014; 304(8):1086–1099; doi: 10.1016/j.ijmm.2014.08.002
Pan American Health Organization. Magnitud y Tendencias de La Resistencia a Los Antimicrobianos En Latinoamérica. RELAVRA 2014, 2015, 2016. Informe Resumido. 2020.
WangS-H, HinesL, van BalenJ, et al.Molecular and clinical characteristics of hospital and community onset methicillin-resistant Staphylococcus aureus strains associated with bloodstream infections. J Clin Microbiol, 2015; 53(5):1599–1608; doi: 10.1128/JCM.03147-14
39.
DhawanB, RaoC, UdoEE, et al.Dissemination of methicillin-resistant Staphylococcus aureus SCCmec type IV and SCCmec type V epidemic clones in a tertiary hospital: Challenge to infection control. Epidemiol Infect, 2015; 143(2):343–353; doi: 10.1017/S095026881400065X
40.
BalAM, CoombsGW, HoldenMTG, et al.Genomic insights into the emergence and spread of international clones of healthcare-, community- and livestock-associated meticillin-resistant Staphylococcus aureus: Blurring of the traditional definitions. J Glob Antimicrob Resist, 2016; 6:95–101; doi: 10.1016/j.jgar.2016.04.004
41.
CollF, HarrisonEM, TolemanMS, et al.Longitudinal genomic surveillance of MRSA in the UK reveals transmission patterns in hospitals and the community. Sci Transl Med, 2017; 9(413):eaak9745; doi: 10.1126/scitranslmed.aak9745
Di GregorioS, VielmaJ, HaimMS, et al.Genomic epidemiology of Staphylococcus aureus isolated from bloodstream infections in South America during 2019 supports regional surveillance. Microb Genomics, 2023; 9(5):mgen001020; doi: 10.1099/mgen.0.001020
44.
LaabeiM, UhlemannA-C, LowyFD, et al.Evolutionary trade-offs underlie the multi-faceted virulence of Staphylococcus aureus. PLoS Biol, 2015; 13(9); doi: 10.1371/journal.pbio.1002229
45.
ChambersHF, DeleoFR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol, 2009; 7(9):629–641; doi: 10.1038/nrmicro2200
46.
HoldenMTG, HsuL-Y, KurtK, et al.A genomic portrait of the emergence, evolution, and global spread of a methicillin-resistant Staphylococcus aureus pandemic. Genome Res, 2013; 23(4):653–664; doi: 10.1101/gr.147710.112
47.
Jiménez MartínezJM, Bebianno Simões M. Migración internacional en las Américas: Tercer informe del Sistema Continuo de Reportes sobre Migración Internacional en las Américas (SICREMI) 2015; 2015.
48.
Ministerio del Interior, Obras Públicas y Vivienda de la NAP. Panorama Movimientos Migratorios 2011–2015; 2016.
49.
Dirección Nacional de Población, Ministerio del Interior Argentina. La Migración Reciente En La Argentina Entre 2012 y 2020; 2021.
50.
TenoverFC, McDougalLK, GoeringRV, et al.Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol, 2006; 44(1):108–118; doi: 10.1128/JCM.44.1.108-118.2006
51.
Nimmo GR. USA300 abroad: Global spread of a virulent strain of community-associated methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect, 2012; 18(8):725–734; doi: 10.1111/j.1469-0691.2012.03822.x
52.
PlanetPJ, DiazL, KolokotronisS-O, et al.Parallel epidemics of community-associated methicillin-resistant Staphylococcus aureus USA300 infection in North and South America. J Infect Dis, 2015; 212(12):1874–1882; doi: 10.1093/infdis/jiv320
53.
RibeiroA, DiasC, Silva-CarvalhoMC, et al.First report of infection with community-acquired methicillin-resistant Staphylococcus aureus in South America. J Clin Microbiol, 2005; 43(4):1985–1988; doi: 10.1128/JCM.43.4.1985-1988.2005
MasimML, ArgimónS, EspirituHO, et al.Genomic surveillance of methicillin-resistant Staphylococcus aureus in the Philippines, 2013–2014. West Pac Surveill Response J WPSAR, 2021; 12(1):6–16; doi: 10.5365/wpsar.2020.11.1.004
56.
FernandezS, LedoC, LattarS, et al.High virulence of methicillin resistant Staphylococcus aureus ST30-SCCmecIVc-spat019, the dominant community-associated clone in Argentina. Int J Med Microbiol IJMM, 2017; 307(4–5):191–199; doi: 10.1016/j.ijmm.2017.05.003
57.
HowdenBP, DaviesJK, JohnsonPDR, et al.Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev, 2010; 23(1):99–139; doi: 10.1128/CMR.00042-09.
58.
UçkayI, BernardL, BuzziM, et al.High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother, 2012; 56(3):1258–1264; doi: 10.1128/AAC.05808-11
59.
Abelenda AlonsoG, Corbacho LoarteMD, Núñez RamosR, et al.Staphylococcus aureus bacteremia in a secondary level Spanish hospital: Clinical implications of high vancomycin MIC. Rev Espanola Quimioter, 2018; 31(4):353–362.
60.
MoisePA, SakoulasG, ForrestA, et al.Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother, 2007; 51(7):2582–2586; doi: 10.1128/AAC.00939-06
61.
WangG, HindlerJF, WardKW, et al.Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol, 2006; 44(11):3883–3886; doi: 10.1128/JCM.01388-06
62.
WangJ-L, WangJ-T, ChenS-Y, et al.Distribution of Staphylococcal cassette chromosome mec Types and correlation with comorbidity and infection type in patients with MRSA bacteremia. PLoS One, 2010; 5(3):e9489; doi: 10.1371/journal.pone.0009489
63.
MaorY, HaginM, BelausovN, et al.Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis, 2009; 199(5):619–624; doi: 10.1086/596629
64.
HolmesNE, JohnsonPDR, HowdenBP. Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections. J Clin Microbiol, 2012; 50(8):2548–2552; doi: 10.1128/JCM.00775-12
65.
ShariatiA, DadashiM, MoghadamMT, et al.Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: A systematic review and meta-analysis. Sci Rep, 2020; 10(1):12689; doi: 10.1038/s41598-020-69058-z
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
